高级检索
当前位置: 首页 > 详情页

Effect of a mentor-based, supportive-expressive program, Be Resilient to Breast Cancer, on survival in metastatic breast cancer: a randomised, controlled intervention trial

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ SSCI

机构: [1]Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510006, China [2]College of Economics andManagement, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510006, China [3]Sun Yat-senUniversity Cancer Center, Guangzhou, Guangdong Province 510060, China [4]The First Affiliated Hospital, Guangzhou University ofChinese Medicine, Guangzhou, Guangdong Province 510405, China [5]The Second Affiliated Hospital, Guangzhou University ofChinese Medicine, Guangzhou, Guangdong Province 510120, China
出处:
ISSN:

关键词: metastatic breast cancer BRBC multidiscipline mentor-based resilience survival group therapy psychosocial support

摘要:
Background: Because of medical advances, metastatic breast cancer (MBC) is now viewed as a chronic disease, rather than an imminent death sentence. Helping women live with this disease requires more than a medical approach to symptoms. Thus, a mentor-based and supportive-expressive program 'Be Resilient to Breast Cancer' (BRBC) was designed to help Chinese women with MBC enhance their resilience levels, biopsychosocial functions, and potentially extend their life span. Methods: A total of 226 women with MBC were randomly assigned, in a 1 : 1 ratio, to an intervention group (IG) that participated in BRBC or to a control group (CG) that received no intervention. Be Resilient to Breast Cancer was conducted for 120 min once a week. Primary outcomes were cancer-specific survival and secondary outcomes were resilience, Allostatic Load Index (ALI), anxiety, depression, and quality of life (QoL). The Cox proportional-hazards model was used for survival analysis and growth mixture models were performed for secondary outcomes. Results: Be Resilient to Breast Cancer did not significantly prolong 3-or 5-year survival (median survival, 36.7 months in IG and 31.5 months in CG). The hazard ratio for death was 0.736 (95% CI, 0.525-1.133, P = 0.076; univariate Cox model) and 0.837 (95% CI, 0.578-1.211, P = 0.345; multivariate Cox analysis). The IG improved in anxiety (ES = 0.85, P<0.001), depression (ES = 0.95, P<0.001), QoL (ES = 0.55, P<0.001), resilience (ES = 0.67, P<0.001), and ALI (ES = 0.90, P<0.001) compared to CG. Conclusions: BRBC does not improve survival of women with MBC in this study, though longer follow up is warranted. It positively impacts resilience, QoL, ALI, and emotional distress.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学
JCR分区:
出版当年[2015]版:
Q1 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510006, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号